Reconsidering the Role of Bone Marrow Aspirate in Modern Spinal Fusion

A Clinically Pragmatic Review of the Evidence

Key Takeaways

• Bone marrow aspirate functions as a biologic component within a fusion construct, with its contribution dependent on technique, biologic dose, and compatibility with the graft material used.

• Cell dose and retention matter. Variability in historical outcomes may reflect dilution, delivery, and early harvesting limitations rather than an absence of marrow-derived biologic effect.

• Clinical and translational studies suggest marrow augmentation can enhance fusion biology and, in selected degenerative settings, achieve outcomes comparable to iliac crest autograft when incorporated into synthetic or allogeneic graft constructs.

• The clinical cost of fusion failure in spine surgery is high, particularly in revision and long-construct cases, supporting consideration of low-risk adjunctive strategies that may incrementally improve biologic performance.

• Advances in aspiration technique and technology have reduced prior barriers, improving consistency and feasibility without materially increasing operative time.

1. Executive Summary

Bone marrow aspirate (BMA) has long been considered a biologically appealing adjunct in spinal fusion, yet its clinical adoption has been inconsistent. Early enthusiasm was tempered by workflow concerns, and uncertainty regarding its incremental value relative to established grafting strategies. As a result, many surgeons have come to view BMA as unreliable or clinically inconsequential.

A review of more recent clinical and translational studies suggests that this conclusion may warrant re-examination. When harvested appropriately and used as an adjunct to synthetic and non–iliac crest autograft bone materials, studies suggest that bone marrow aspirate or bone marrow concentrate (BMC) can enhance fusion biology, achieve outcomes equivalent to iliac crest bone graft (ICBG) in selected settings, and serve as a low-risk alternative to bone morphogenetic protein (BMP) in appropriate patients [1–4].

BMA’s potential value appears to depend on technique, biologic dose, and the graft environment in which it is delivered. This white paper reviews the clinical and translational literature supporting this interpretation, with a focus on degenerative spinal fusion procedures commonly performed in community and academic practice.

2. Why Bone Marrow Aspirate Fell Out of Favor — and Why That View May Be Outdated

Bone marrow aspirate has occupied an uncertain position in spinal fusion for decades. The biologic rationale—introducing marrow-derived cells and signaling factors into the fusion environment—was compelling. However, clinical experience may not always show obvious and dramatic results at a glance at the level of individual cases, leading many surgeons to abandon its use.

This skepticism is understandable. Earlier studies evaluating BMA often suffered from heterogeneous methodologies, limited sample sizes, and inconsistent graft constructs. In many cases, aspiration technique, aspirate volume, degree of peripheral blood dilution, and cellular content were neither standardized nor measured. Under these conditions, any biologic contribution from marrow would be expected to be modest and difficult to detect on a case-by-case basis, even if a true biologic signal existed at the level of a larger sample size.

More recent investigations suggest an alternative explanation. Rather than indicating a lack of biologic potential, variability in reported outcomes may reflect differences in how marrow was harvested, processed, and retained within the graft environment. Contemporary studies seem to more effectively control graft constructs, compare treatments within the same patient, or include cellular analyses provide a more nuanced understanding of where BMA may contribute meaningfully to fusion biology.

A prospective, randomized, controlled, and blinded study of instrumented posterolateral lumbar fusion demonstrated higher fusion rates when bone marrow concentrate was added to cancellous allograft compared with allograft alone, based on both radiographic and CT-based assessments [1]. Such findings suggest that earlier conclusions drawn from uncontrolled or diluted marrow techniques may not fully reflect the biologic potential of marrow augmentation.

The implications of this distinction are particularly important in spine surgery. Unlike long-bone fractures, where delayed union or nonunion can often be managed non-surgically or with minimal surgical intervention, a failed spinal fusion frequently results in persistent pain, progressive deformity, instrumentation failure, and the need for complex revision surgery. As a result, primary spinal surgery often involves a multi-modal biologic approach reflecting the high clinical cost of failure. In this context, relatively low-risk adjunctive strategies such as bone marrow aspirate, that may incrementally improve fusion biology warrant consideration.

3. Fusion Biology Refresher: Where Bone Marrow Aspirate May Contribute

The research is clear that successful spinal fusion requires the integration of osteoconduction, osteoinduction, and osteogenesis. While modern instrumentation reliably addresses mechanical stability and a wide array of graft materials provide a scaffold, most commonly used non-autograft materials lack intrinsic cellular content. 

Bone marrow aspirate does not replace the need for structural support, adequate fixation, or sufficient graft volume. Its proposed role is to enhance the biologic environment by introducing marrow-derived cells and associated factors into a graft construct that may otherwise be biologically limited.

Translational work by Muschler and colleagues provides important insight into this mechanism. In posterior spinal fusion models, graft constructs enriched with marrow-derived cells demonstrated improved fusion outcomes compared with matrix alone. Further, strategies designed to selectively retain marrow-derived cells within the graft environment further enhanced fusion performance [6,7].

These findings suggest two clinically relevant principles. First, the presence and retention of marrow-derived cells may influence fusion outcomes. Second, effective delivery of marrow biology requires compatibility between the biologic component and the scaffold and fixation environment.

4. What the Clinical Evidence Suggests: Bone Marrow Aspirate as a Biologic Enhancer

4.1 Enhancement of Allograft Performance

Several studies in the reviewed literature address whether marrow augmentation can improve the performance of non-autograft materials. In the randomized, blinded study of degenerative posterolateral lumbar fusion, Hart and colleagues demonstrated higher fusion rates and greater bridging bone when bone marrow concentrate was combined with cancellous allograft compared with allograft alone [1].

Although posterolateral fusion is not the dominant approach in many current degenerative practices, this study is notable for isolating the biologic variable while holding fixation constant. The findings suggest that marrow augmentation may partially compensate for the absence of osteogenic potential in allograft constructs.

4.2 Equivalence to Iliac Crest Autograft in Selected Settings

A prospective randomized study comparing cancellous allograft combined with autologous bone marrow concentrate to iliac crest bone graft reported no statistically significant differences in fusion outcomes across lateral gutters, interbody cages, and facet joints. Cellular analyses demonstrated a positive trend between CD34+ cell counts and radiographic fusion scores [2].

A separate randomized study evaluating posterolateral lumbar fusion compared iliac crest autograft with local laminectomy bone chips mixed with bone marrow aspirate. Fusion rates were similar between constructs, while calcium sulfate pellets soaked in BMA performed significantly worse.  Arguably, calcium sulfate is a sub-optimal bone graft substitute for fusion applications; this study underscores that marrow does not uniformly rescue all graft substrates [4].

4.3 Cervical Fusion and Fusion Kinetics

In anterior cervical discectomy and fusion, where baseline fusion rates are often high, marrow augmentation may influence the timing rather than the incidence of fusion. A retrospective cohort study demonstrated similar final fusion rates but a higher probability of fusion at earlier time points when BMA was incorporated into the graft construct [5].

5. Dose and Technique: Interpreting Variability in Reported Outcomes

A recurring theme across both clinical and translational studies is that marrow should not be viewed as a binary variable. Simply adding aspirate does not ensure biologic equivalence across cases.

Clinical data demonstrate trends linking higher cellular content with improved radiographic fusion [2]. Translational work further demonstrates stepwise improvements in fusion outcomes as graft constructs deliver and retain greater numbers of marrow-derived cells [6,7].

These findings suggest that cell dose and retention within the graft environment are critical determinants of efficacy. Dilution with peripheral blood or delivery methods that fail to retain cells at the fusion site may reduce the likelihood of observing clinical benefit.

6. Clinical Context: Where Bone Marrow Aspirate May Fit Today

Based on the reviewed evidence, marrow augmentation appears most relevant in degenerative fusion settings where non-ICBG grafts are used and where enhancing biologic potential may reduce reliance on more aggressive biologics.

Procedures where BMA may be most applicable include lumbar and thoracic interbody fusions, with cervical fusion representing a setting where accelerated fusion kinetics may be beneficial. Posterolateral fusion remains a relevant model for biologic comparison, but with the growth of MIS approaches is a less common procedure in contemporary practice.

Adult spinal deformity represents a distinct but highly relevant biologic challenge. Long constructs frequently require graft volumes that exceed what can reasonably be harvested as autograft, necessitating supplementation with cancellous allograft or synthetic extenders that lack cellular components. In this setting, bone marrow aspirate may provide added biologic value by reintroducing cellular and signaling elements across a large fusion surface area.

6.5 Technology Evolution and Practical Feasibility

Early clinical experience with bone marrow aspirate was shaped by the limitations of available harvesting tools. Traditional single-port Jamshidi needles are poorly suited for biologic harvesting due to rapid peripheral blood dilution and limited control over aspirate quality.  Subsequent advances introduced fenestrated needles with open distal tips, allowing aspiration from multiple marrow channels and improving cellular yield.

Bone marrow aspirate concentration (BMAC) improves the cellular load by removing some of the peripheral blood contamination through centrifugation.  In the process, concentration may remove some valuable biologic constituents, but this adds time, cost, and infection risk to the procedure.  It often requires 120 cc’s or more to yield a clinically relevant amount of BMAC, which is often overlooked in calculating operative blood loss.

To address some of the drawbacks of BMAC, non-centrifugation technology has been introduced that limits peripheral blood ingress and permits controlled, sequential aspiration along the needle tract.  Additionally, one device has redesigned the aspiration needle ports to leverage fluid dynamic principles that appear to result in fold increases in cellular load over BMAC.

Collectively, these developments have improved the consistency, efficiency, and practicality of marrow harvesting, addressing earlier workflow and dose-related concerns without altering the underlying biologic premise.

7. Conclusion

Bone marrow aspirate should not be viewed as a replacement for sound surgical planning, stable fixation, or appropriate graft selection.

The current evidence base remains limited by study size, heterogeneity of technique, and variability in outcome assessment. Larger, well-controlled studies will be necessary to further define optimal patient selection, dosing, and procedure-specific benefit.

Nevertheless, the available clinical and translational literature suggests that when harvested with attention to technique and used as an adjunct to biologically compatible non-ICBG grafts, bone marrow aspirate can meaningfully contribute to fusion biology. In settings where the clinical cost of failure is high and graft constructs lack intrinsic cellular content, BMA represents a pragmatic, low-risk strategy that may be worth incorporating into modern spinal fusion practice.

Questions or perspectives on how marrow-based strategies fit into your current fusion workflows are always welcome. I’m happy to discuss how others are approaching biologic supplementation in degenerative, revision, and long-construct cases.  Email me at kparmstrong@blackswan360.com to explore this topic further.

Bibliography

1)    Hart R, et al.Allograft alone versus allograft with bone marrow concentrate for the healing of the instrumented posterolateral lumbar fusion. The Spine Journal. 2014;14(7):1318–1324.

2)    Kitchel SH.A preliminary comparative study of radiographic results using mineralized collagen and bone marrow aspirate versus autologous bone in the same patients undergoing posterior lumbar interbody fusion with instrumented posterolateral lumbar fusion. The Spine Journal. 2006;6(4):405–411.

3)    Johnson RG.Bone marrow concentrate with allograft equivalent to autograft in lumbar fusions. Spine. 2014;39(9):695–700.

4)    Niu CC, Tsai TT, Fu TS, Lai PL, Chen LH, Chen WJ.A comparison of posterolateral lumbar fusion comparing autograft, autogenous laminectomy bone with bone marrow aspirate, and calcium sulphate with bone marrow aspirate: a prospective randomized study. Spine. 2009;34(25):2715–2719.

5)    Barber SM, Radaideh M, Parrish R.Efficacy of autogenous bone marrow aspirate as a fusion-promoting adjunct to anterior cervical discectomy and fusion: a single-center retrospective cohort study. Cureus. 2018;10(5):e2636.

6)    Muschler GF, Nitto H, Matsukura Y, et al.Spine fusion using cell–matrix composites enriched in bone marrow–derived cells. Clinical Orthopaedics and Related Research. 2003;(407):102–118.

7)    Muschler GF, Matsukura Y, Nitto H, et al.Selective retention of bone marrow–derived cells to enhance spinal fusion. Clinical Orthopaedics and Related Research. 2005;(432):242–251. doi:10.1097/01.blo.0000149812.32857.8b

8)    Teixeira AFOP.The Use of Bone Marrow Aspirate in Lumbar Spinal Fusion. Master’s Dissertation. Faculty of Medicine, University of Porto; 2023.